Literature DB >> 8598496

TGF-beta contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice.

H Maeda1, A Shiraishi.   

Abstract

In previous reports, we showed that tumor-derived TGF-beta induced overproduction of IL-10, and these suppressive cytokines caused macrophage suppression in EL4-bearing mice. Proliferation of T cells from EL-4, but not IL-2, whereas T cells from normal mice were responsive to IL-2. A balance between Th1- and Th2-type cytokine production in EL4-T in response to anti-CD3 Ab or phorbor myristate acetate plus A23187 shifted toward the Th2 dominant pattern. The prevention of TGF-beta and IL-10 activates in vivo by administration of anti-IL-10 Ab (anti-IL-10) or anti TGF-beta Ab (anti-TGF-beta) resulted in the reduction in EL4-T of both IL-4 dependent proliferation and Th2-dominant cytokine production induced by anti-CD-3 stimulation. In addition, the anti-TGF-beta treatment resulted in complete restoration in EL4-T of suppressed IL-2 responsiveness, IL-2R expression, and Th1-type cytokine production, whereas the anti-IL-10 treatment produced partial recovery. These results lead us to conclude that TGF-beta drives the shift in the Th1/Th2 balance toward Th2 via IL-10-mediated development of the Th2 responses and via inhibition of the Th1-type responses directly in EL4-bearing mice.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8598496

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  47 in total

Review 1.  Th1/Th2 balance in cancer, transplantation and pregnancy.

Authors:  M R Shurin; L Lu; P Kalinski; A M Stewart-Akers; M T Lotze
Journal:  Springer Semin Immunopathol       Date:  1999

Review 2.  Interplay between Circadian Clock and Cancer: New Frontiers for Cancer Treatment.

Authors:  Gabriele Sulli; Michael Tun Yin Lam; Satchidananda Panda
Journal:  Trends Cancer       Date:  2019-08-03

Review 3.  TGFβ in T cell biology and tumor immunity: Angel or devil?

Authors:  Eric Tu; Pei Zhi Cheryl Chia; Wanjun Chen
Journal:  Cytokine Growth Factor Rev       Date:  2014-07-29       Impact factor: 7.638

4.  Production of interleukin-10 and transforming growth factor beta by peripheral blood mononuclear cells in Q fever endocarditis.

Authors:  C Capo; Y Zaffran; F Zugun; P Houpikian; D Raoult; J L Mege
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

5.  Measurement of T-cell-derived antigen binding molecules and immunoglobulin G specific to Candida albicans mannan in sera of patients with recurrent vulvovaginal candidiasis.

Authors:  C H Little; G M Georgiou; A Marceglia; H Ogedgebe; R E Cone; D Mazza
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

Review 6.  TGFβ as a therapeutic target in cystic fibrosis.

Authors:  Elizabeth L Kramer; John P Clancy
Journal:  Expert Opin Ther Targets       Date:  2017-12-13       Impact factor: 6.902

7.  Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity.

Authors:  Denise L Cecil; Gregory E Holt; Kyong Hwa Park; Ekram Gad; Lauren Rastetter; Jennifer Childs; Doreen Higgins; Mary L Disis
Journal:  Cancer Res       Date:  2014-04-28       Impact factor: 12.701

8.  Cytokine expression in squamous intraepithelial lesions of the uterine cervix: implications for the generation of local immunosuppression.

Authors:  S L Giannini; W Al-Saleh; H Piron; N Jacobs; J Doyen; J Boniver; P Delvenne
Journal:  Clin Exp Immunol       Date:  1998-08       Impact factor: 4.330

9.  Colon carcinoma cell lines stimulate monocytes and lamina propria mononuclear cells to produce IL-10.

Authors:  T Kucharzik; N Lügering; G Winde; W Domschke; R Stoll
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

10.  Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines.

Authors:  Ryo Ueda; Mitsugu Fujita; Xinmei Zhu; Kotaro Sasaki; Edward R Kastenhuber; Gary Kohanbash; Heather A McDonald; Jay Harper; Scott Lonning; Hideho Okada
Journal:  Clin Cancer Res       Date:  2009-10-27       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.